Literature DB >> 11481614

Leptin augments inflammatory and profibrogenic responses in the murine liver induced by hepatotoxic chemicals.

K Ikejima1, H Honda, M Yoshikawa, M Hirose, T Kitamura, Y Takei, N Sato.   

Abstract

Lines of evidence suggested a possible link between leptin and hepatic fibrosis; however, whether leptin modulates the fibrogenesis in the liver remains unclear. The purpose of this study, therefore, was to evaluate the effect of leptin on inflammatory and profibrogenic responses in the liver caused by hepatotoxic chemicals. Male C57Bl/6 mice were given carbon tetrachloride (CCl(4)) (0.1 microL/g body weight [BW], intraperitoneally [IP]) and/or recombinant murine leptin (1 microg/g BW, IP) simultaneously, and sacrificed up to 72 hours later. Further, some mice were given thioacetamide (TAA; 200 microg/g BW, IP) and leptin 3 times per week for 4 weeks to evaluate the effect of leptin on chronic fibrogenic responses. A simultaneous injection of leptin enhanced acute CCl(4)-induced necroinflammatory and subsequent fibrotic changes in the hepatic lobules. The steady-state messenger RNA (mRNA) levels of alpha1(I) procollagen and heat shock protein 47 (HSP47) in the liver were potentiated when leptin was injected together with CCl(4). Expression of alpha smooth muscle actin (alpha-SMA) in the liver after CCl(4) treatment was also augmented markedly in combination with leptin. Further, leptin increased transforming growth factor beta1 (TGF-beta1) mRNA in the liver 24 hours after acute CCl(4) about 4-fold higher than CCl(4) alone. Moreover, leptin enhanced hepatic fibrosis and induction of alpha1(I) procollagen mRNA caused by chronic TAA administration. Collectively, these findings indicated that leptin augments both inflammatory and profibrogenic responses in the liver caused by hepatotoxic chemicals. It is postulated that the increase in systemic leptin levels enhances up-regulation of TGF-beta1, leading to activation of stellate cells, thereby augmenting the fibrogenic response in the liver.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11481614     DOI: 10.1053/jhep.2001.26518

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  79 in total

1.  Zinc mediated hepatic stellate cell collagen synthesis reduction through TGF-β signaling pathway inhibition.

Authors:  Min Kang; Lei Zhao; Meiping Ren; Mingming Deng; Changping Li
Journal:  Int J Clin Exp Med       Date:  2015-11-15

2.  miR-33a levels in hepatic and serum after chronic HBV-induced fibrosis.

Authors:  Chuan-Feng Huang; Cheng-Chao Sun; Fang Zhao; Ya-Dong Zhang; De-Jia Li
Journal:  J Gastroenterol       Date:  2014-08-26       Impact factor: 7.527

3.  Leptin increases tissue inhibitor of metalloproteinase I (TIMP-1) gene expression by a specificity protein 1/signal transducer and activator of transcription 3 mechanism.

Authors:  Songbai Lin; Neeraj K Saxena; Xiaokun Ding; Lance L Stein; Frank A Anania
Journal:  Mol Endocrinol       Date:  2006-08-24

4.  The efficacy of adipokines and indices of metabolic syndrome as predictors of severe obesity-related hepatic steatosis.

Authors:  Nahum Méndez-Sánchez; Norberto C Chávez-Tapia; Roberto Medina-Santillán; Antonio R Villa; Karla Sánchez-Lara; Guadalupe Ponciano-Rodríguez; Martha H Ramos; Misael Uribe
Journal:  Dig Dis Sci       Date:  2006-10       Impact factor: 3.199

Review 5.  Gene modulation for treating liver fibrosis.

Authors:  Kun Cheng; Ram I Mahato
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  2007       Impact factor: 4.889

6.  Current and novel therapies for the treatment of nonalcoholic steatohepatitis.

Authors:  David van der Poorten; Jacob George
Journal:  Hepatol Int       Date:  2007-07-26       Impact factor: 6.047

7.  Proinflammatory adipokine leptin mediates disinfection byproduct bromodichloromethane-induced early steatohepatitic injury in obesity.

Authors:  Suvarthi Das; Ashutosh Kumar; Ratanesh Kumar Seth; Erik J Tokar; Maria B Kadiiska; Michael P Waalkes; Ronald P Mason; Saurabh Chatterjee
Journal:  Toxicol Appl Pharmacol       Date:  2013-02-22       Impact factor: 4.219

Review 8.  Treatment of hepatic fibrosis: almost there.

Authors:  Efsevia Albanis; Rifaat Safadi; Scott L Friedman
Journal:  Curr Gastroenterol Rep       Date:  2003-02

9.  Risk factors and mechanisms of non-alcoholic steatohepatitis.

Authors:  Chantal A Rivera
Journal:  Pathophysiology       Date:  2008-07-29

10.  Association of leptin -2548G/A and leptin receptor Q223R polymorphisms with increased risk for oral cancer.

Authors:  Christos Yapijakis; Michael Kechagiadakis; Emeka Nkenke; Zoe Serefoglou; Dimitrios Avgoustidis; Antonis Vylliotis; Despina Perrea; Friedrich W Neukam; Efstratios Patsouris; Eleftherios Vairaktaris
Journal:  J Cancer Res Clin Oncol       Date:  2008-10-15       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.